Bristol Myers Squibb (CELG-RI) Raw Materials (2010 - 2013)
Bristol Myers Squibb's (CELG-RI) quarterly Raw Materials came in at $338.0 million in Q1 2013, up 40.25% year-over-year from $241.0 million in Q1 2012, and up 24.72% quarter-over-quarter from $271.0 million in Q4 2012.
Analysis
Bristol Myers Squibb (CELG-RI) Raw Materials (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Raw Materials for 4 consecutive years, with $338.0 million the latest figure, recorded in Q1 2013.
- On a quarterly basis, Raw Materials rose 40.25% year-over-year to $338.0 million in Q1 2013; TTM through Mar 2013 was $338.0 million, a 40.25% increase from a year earlier, with the FY2012 full-year figure at $271.0 million, up 4.23% from the prior year.
- Raw Materials was $338.0 million for Q1 2013 at Bristol Myers Squibb, up from $271.0 million in the prior quarter.
- Over five years, Raw Materials peaked at $357.0 million in Q2 2011 and troughed at $199.0 million in Q4 2010.
- A 4-year average of $264.8 million and a median of $261.5 million in 2011 frame the typical range for Raw Materials.
- The widest YoY moves for Raw Materials: up 44.39% in 2012, down 26.33% in 2012.
- Over 4 years, Raw Materials stood at $199.0 million in 2010, then surged by 30.65% to $260.0 million in 2011, then gained by 4.23% to $271.0 million in 2012, then rose by 24.72% to $338.0 million in 2013.
- The last three Raw Materials figures came in at $338.0 million (Q1 2013), $271.0 million (Q4 2012), and $296.0 million (Q3 2012), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.60 Bn | 621.84 Bn | 17.26 Bn |
| 2 | AbbVie | 447.11 Bn | 440.55 Bn | 12.70 Bn |
| 3 | Merck | 358.25 Bn | 351.11 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.57 Bn | 259.88 Bn | 11.24 Bn |
| 5 | Pfizer | 156.64 Bn | 144.94 Bn | 10.94 Bn |
| 6 | Sanofi | 52.20 Bn | 44.82 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - |
| 8 | Incyte | 24.64 Bn | 20.11 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2013 | 338.00 Mn |
| Dec 31, 2012 | 271.00 Mn |
| Sep 30, 2012 | 296.00 Mn |
| Jun 30, 2012 | 263.00 Mn |
| Mar 31, 2012 | 241.00 Mn |
| Dec 31, 2011 | 260.00 Mn |
| Sep 30, 2011 | 205.00 Mn |
| Jun 30, 2011 | 357.00 Mn |
| Mar 31, 2011 | 218.00 Mn |
| Dec 31, 2010 | 199.00 Mn |